WallStreetZenWallStreetZen

NASDAQ: SPRO
Spero Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SPRO

Based on 2 analysts offering 12 month price targets for Spero Therapeutics Inc

Min Forecast
$5.00+508.27%
Avg Forecast
$5.00+508.27%
Max Forecast
$5.00+508.27%

Should I buy or sell SPRO stock?

Based on 2 analysts offering ratings for Spero Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SPRO stock forecasts and price targets.

SPRO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-01-30
lockedlocked$00.00+00.00%2024-12-20

1 of 1

Forecast return on equity

Is SPRO forecast to generate an efficient return?

Company
-42.44%
Industry
8,502.9%
Market
195.87%
SPRO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SPRO forecast to generate an efficient return on assets?

Company
-20.57%
Industry
3,475.72%
SPRO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SPRO earnings per share forecast

What is SPRO's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.84-1,150%
Avg 2 year Forecast
-$0.51-737.5%

SPRO revenue forecast

What is SPRO's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$60.0M-43.64%
SPRO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SPRO revenue growth forecast

How is SPRO forecast to perform vs Biotechnology companies and vs the US market?

Company
-43.64%
Industry
2,978.32%
Market
58.57%
SPRO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SPRO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SPRO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SPRO$0.82$5.00+508.27%Buy
CNTB$0.82N/AN/A
IBIO$4.63$6.00+29.59%Strong Buy
OKYO$1.35$7.00+418.52%Buy
ICCC$4.91N/AN/A
View Top Biotech Stocks

Spero Therapeutics Stock Forecast FAQ

Is Spero Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: SPRO) stock is to Buy SPRO stock.

Out of 2 analysts, 0 (0%) are recommending SPRO as a Strong Buy, 1 (50%) are recommending SPRO as a Buy, 1 (50%) are recommending SPRO as a Hold, 0 (0%) are recommending SPRO as a Sell, and 0 (0%) are recommending SPRO as a Strong Sell.

If you're new to stock investing, here's how to buy Spero Therapeutics stock.

What is SPRO's earnings growth forecast for 2025-2026?

(NASDAQ: SPRO) Spero Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 46.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 65.75%.

Spero Therapeutics's earnings in 2025 is $3,513,000.On average, 1 Wall Street analyst forecast SPRO's earnings for 2025 to be -$45,795,259, with the lowest SPRO earnings forecast at -$45,795,259, and the highest SPRO earnings forecast at -$45,795,259.

In 2026, SPRO is forecast to generate -$27,804,264 in earnings, with the lowest earnings forecast at -$27,804,264 and the highest earnings forecast at -$27,804,264.

What is SPRO's revenue growth forecast for 2025-2025?

(NASDAQ: SPRO) Spero Therapeutics's forecast annual revenue growth rate of -43.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 2,978.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.57%.

Spero Therapeutics's revenue in 2025 is $106,455,000.

In 2025, SPRO is forecast to generate $3,271,089,900 in revenue, with the lowest revenue forecast at $3,271,089,900 and the highest revenue forecast at $3,271,089,900.

What is SPRO's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: SPRO) forecast ROA is -20.57%, which is lower than the forecast US Biotechnology industry average of 3,475.72%.

What is SPRO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year SPRO price target, the average SPRO price target is $5.00, with the highest SPRO stock price forecast at $5.00 and the lowest SPRO stock price forecast at $5.00.

On average, Wall Street analysts predict that Spero Therapeutics's share price could reach $5.00 by Jan 30, 2026. The average Spero Therapeutics stock price prediction forecasts a potential upside of 508.27% from the current SPRO share price of $0.82.

What is SPRO's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: SPRO) Spero Therapeutics's current Earnings Per Share (EPS) is $0.08. On average, analysts forecast that SPRO's EPS will be -$0.84 for 2025, with the lowest EPS forecast at -$0.84, and the highest EPS forecast at -$0.84. In 2026, SPRO's EPS is forecast to hit -$0.51 (min: -$0.51, max: -$0.51).

What is SPRO's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: SPRO) forecast ROE is -42.44%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.